Szwedziak Krzysztof, Szymański Dariusz, Strzelczyk Janusz
Department of General and Transplant Surgery, Medical University of Lodz, Barlicki University Hospital, Lodz, Poland.
Contemp Oncol (Pozn). 2013;17(4):394-9. doi: 10.5114/wo.2013.35057. Epub 2013 Oct 7.
Pancreatic cancer is one of the most frequent cancers in the world. Only 20% of patients seem to have disease confined to the pancreas, but in only every second case the tumor turns out to be resectable during surgery. Tumor markers may be a useful tool in differentiating benign from malignant pancreatic tumors and in clinical staging. The purpose of the study is to assess CA 125 utility as a predictor of resectability in pancreatic tumor.
66 patients were operated on for pancreatic tumor between October 2010 and July 2012. CA 125 concentration was measured in peripheral and portal blood. 57 patients were diagnosed with malignant and 9 with inflammatory tumor. Seven patients had metastases to the liver. Radical surgery was performed in 34 patients.
Significantly higher CA 125 concentration in portal blood was found in the pancreatic cancer than in the inflammatory tumor group (36.5 ±99.6 vs. 16.4 ±26.5; p < 0.05). CA 125 concentration in peripheral blood and in portal blood as well of patients with malignant pancreatic tumors and with metastases to the liver was significantly higher than in the group without metastases (146.15 ±256.1 vs. 18.5 ±17.5; p < 0.01 and 147.5 ±261.2 vs. 19.7 ±24.3; p < 0.05, respectively). CA 125 values in the group without metastases to the liver and in the case of radical surgery were significantly higher in portal than in peripheral blood (19.7 ±24.3 vs. 18.5 ±17.5; p < 0.001 and 13.2 ±15.0 vs. 13.0 ±15.2; p < 0.001, respectively).
Determination of CA 125 concentration in peripheral blood and in portal blood as well might be a useful tool in differentiating between malignant and inflammatory pancreatic tumors and when decisions on surgery extensiveness are being made.
胰腺癌是全球最常见的癌症之一。仅20%的患者似乎疾病局限于胰腺，但仅在每两例病例中，肿瘤在手术时才被证明可切除。肿瘤标志物可能是区分胰腺良性肿瘤与恶性肿瘤以及临床分期的有用工具。本研究的目的是评估CA 125作为胰腺肿瘤可切除性预测指标的效用。
2010年10月至2012年7月期间，66例患者接受了胰腺肿瘤手术。检测外周血和门静脉血中的CA 125浓度。57例患者被诊断为恶性肿瘤，9例为炎性肿瘤。7例患者有肝转移。34例患者接受了根治性手术。
胰腺癌患者门静脉血中CA 125浓度显著高于炎性肿瘤组（36.5±99.6对16.4±26.5；p<0.05）。恶性胰腺肿瘤患者及有肝转移患者外周血和门静脉血中的CA 125浓度显著高于无转移组（分别为146.15±256.1对18.5±17.5；p<0.01和147.5±261.2对19.7±24.3；p<0.05）。无肝转移组和接受根治性手术患者的门静脉血中CA 125值显著高于外周血（分别为19.7±24.3对18.5±17.5；p<0.001和13.2±15.0对13.0±15.2；p<0.001）。
检测外周血和门静脉血中的CA 125浓度可能是区分胰腺恶性肿瘤与炎性肿瘤以及决定手术范围时的有用工具。
